PresseBox
Pressemitteilung BoxID: 933652 (ARTES Biotechnology GmbH)
  • ARTES Biotechnology GmbH
  • Elisabeth-Selbert-Str. 9
  • 40764 Langenfeld
  • http://www.artes-biotechnology.com
  • Ansprechpartner
  • Melanie Piontek
  • +49 (2173) 2758712

SplitCore – the latest milestone in ARTES´ vaccine development offer

(PresseBox) (Langenfeld, ) ARTES Biotechnology announces the acquisition of the unique SplitCore technology developed by scientists at the University of Freiburg, Germany. Backbone of this platform is a flexible integration and presentation of foreign antigens on the surface of capsid virus like particles (cVLP), which can be produced in bacteria and yeast.

With its yeast based METAVAX® platform for antigen presentation on envelope virus like particles (eVLP´s), ARTES is already well established and a preferred partner for human and animal vaccine development projects. The inclusion of the SplitCore technology in ARTES’ vaccine development portfolio enables the company to offer customers an even broader spectrum of service solutions for the development of their specific vaccines.

“With the two potent and versatile platforms, SplitCore and METAVAX®, we can now offer the full range of nanoparticle based vaccine development, covering both capsid VLP’s and envelope VLP´s. Antigens, ranging from peptide epitopes to complex proteins, are compatible with these technologies and can be manufactured in all major recombinant production platforms including E. coli, yeast and CHO cells”, Volker Jenzelewski, Director Technology of ARTES, said. “SplitCore will substantially complement our capability to address technical and economical challenges our pharmaceutical customers may face. Together with our METAVAX® platform, which already result in several vaccine candidates manufactured, we are now even stronger positioned to support the development of innovative vaccines.”

SplitCore bases on the technology to split the core or capsid protein of Hepatitis B virus into two parts. These splitted core antigens form efficiently nanoparticles known as capsid virus like particles (cVLP). On the surface of those particles, differently structured proteins can be added with a high degree of freedom and will then be presented highly exposed and hence effective to the immune system.

Website Promotion

ARTES Biotechnology GmbH

ARTES Biotechnology is a pharmaceutical contract research & development organization that provides cell line and process development for and manufacturing of bio-pharmaceutical products. The company is a well-established partner for many of the biggest names in the industry, with more than 20 years of business experience, a track record of products developed for and marketed by clients as well as safe, reliable and highly competitive microbial production platforms. ARTES specializes in recombinant protein production, process and vaccine development from microbial expression systems, marketing the unique METAVAX® (dHepB-eVLP) and SplitCore (HepB-cVLP) technology in combination with yeast expression. ARTES operates worldwide from its 850m2 S1 facilities in Langenfeld, from where it also offers cell line engineering based on yeast (Hansenula polymorpha, syn. Pichia angusta; Saccharomyces cerevisiae) and bacterial (E. coli) expression platforms, lab scale up- and downstream process development, supply of non-GMP bulk material (API) for activity and toxicity tests and technology transfer to cGMP facilities and scale-up support.